158 related articles for article (PubMed ID: 38676807)
1. A Semiautomated Proteomics and Phosphoproteomics Protocol for the Identification of Novel Therapeutic Targets and Predictive Biomarkers in In Vivo Xenograft Models of Pediatric Cancers.
Lim Kam Sian TCC; Sun C; Cain JE; Steele JR; Hanchapola I; Stoychev S; Schittenhelm RB; Faridi P
Methods Mol Biol; 2024; 2806():229-242. PubMed ID: 38676807
[TBL] [Abstract][Full Text] [Related]
2. Omics-Based Investigations of Breast Cancer.
Neagu AN; Whitham D; Bruno P; Morrissiey H; Darie CA; Darie CC
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375323
[TBL] [Abstract][Full Text] [Related]
3. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
Liu Z; Liu Y; Qian L; Jiang S; Gai X; Ye S; Chen Y; Wang X; Zhai L; Xu J; Pu C; Li J; He F; Huang M; Tan M
Mol Cell; 2021 Oct; 81(19):4076-4090.e8. PubMed ID: 34375582
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
Lescarbeau RS; Lei L; Bakken KK; Sims PA; Sarkaria JN; Canoll P; White FM
Mol Cancer Ther; 2016 Jun; 15(6):1332-43. PubMed ID: 27196784
[TBL] [Abstract][Full Text] [Related]
5. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line.
Kito F; Oyama R; Sakumoto M; Takahashi M; Shiozawa K; Qiao Z; Sakamoto H; Hirose T; Setsu N; Yoshida A; Kawai A; Kondo T
In Vitro Cell Dev Biol Anim; 2018 Aug; 54(7):528-536. PubMed ID: 29943355
[TBL] [Abstract][Full Text] [Related]
7. The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine.
Doll S; Gnad F; Mann M
Proteomics Clin Appl; 2019 Mar; 13(2):e1800113. PubMed ID: 30790462
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer.
Tong M; Yu C; Zhan D; Zhang M; Zhen B; Zhu W; Wang Y; Wu C; He F; Qin J; Li T
EBioMedicine; 2019 Feb; 40():305-317. PubMed ID: 30594550
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
Clin Cancer Res; 2024 Feb; 30(4):849-864. PubMed ID: 37703185
[TBL] [Abstract][Full Text] [Related]
12. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
13. RUPE-phospho: Rapid Ultrasound-Assisted Peptide-Identification-Enhanced Phosphoproteomics Workflow for Microscale Samples.
Huang Y; Shao X; Liu Y; Yan K; Ying W; He F; Wang D
Anal Chem; 2023 Dec; 95(49):17974-17980. PubMed ID: 38011496
[TBL] [Abstract][Full Text] [Related]
14. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.
Kubota D; Mukaihara K; Yoshida A; Tsuda H; Kawai A; Kondo T
J Proteomics; 2013 Oct; 91():393-404. PubMed ID: 23911960
[TBL] [Abstract][Full Text] [Related]
15. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS
Cancer Biol Ther; 2018; 19(12):1078-1087. PubMed ID: 30299205
[TBL] [Abstract][Full Text] [Related]
16. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist.
Weigand S; Herting F; Maisel D; Nopora A; Voss E; Schaab C; Klammer M; Tebbe A
Cancer Res; 2012 Sep; 72(17):4329-39. PubMed ID: 22777824
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues.
Sun X; Chang J; Zhou C; Zhao P; Guo S; Tong J; Wang Y; Yang Y
J Vis Exp; 2024 Mar; (205):. PubMed ID: 38587398
[TBL] [Abstract][Full Text] [Related]
19. Proteomics and phosphoproteomics in precision medicine: applications and challenges.
Giudice G; Petsalaki E
Brief Bioinform; 2019 May; 20(3):767-777. PubMed ID: 29077858
[TBL] [Abstract][Full Text] [Related]
20. Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection.
Labots M; van der Mijn JC; Beekhof R; Piersma SR; de Goeij-de Haas RR; Pham TV; Knol JC; Dekker H; van Grieken NCT; Verheul HMW; Jiménez CR
J Proteomics; 2017 Jun; 162():99-107. PubMed ID: 28442448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
